Appili Therapeutics (OTCMKTS:APLIF) Issues Earnings Results

Appili Therapeutics (OTCMKTS:APLIF) posted its quarterly earnings data on Tuesday. The company reported ($0.01) EPS for the quarter, meeting the consensus estimate of ($0.01), Yahoo Finance reports.

Appili Therapeutics Stock Performance

Shares of APLIF stock remained flat at $0.02 during trading on Wednesday. The stock has a market capitalization of $2.92 million, a P/E ratio of -0.80 and a beta of -0.49. The stock has a 50-day moving average of $0.03 and a two-hundred day moving average of $0.03. Appili Therapeutics has a 12 month low of $0.02 and a 12 month high of $0.07.

Appili Therapeutics Company Profile

Appili Therapeutics Inc, a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis.